Literature DB >> 6585185

Cerebrospinal fluid enolase isoenzymes and neurotoxicity in early treatment of lymphoblastic leukaemia.

J A Royds, J S Lilleyman, W R Timperley, C B Taylor.   

Abstract

Serial measurements of enolase in the cerebrospinal fluid were made in 19 children with lymphoblastic leukaemia undergoing their first 6 weeks of antineoplastic treatment. The neurone-specific gamma enolase value rose appreciably in nearly all patients during the first two weeks of treatment, which comprised chemotherapy only, but the mean values for this isoenzyme failed to show any further rise during the subsequent cranial irradiation. In contrast the alpha enolase value, which is derived predominantly from glial tissue, rose progressively to attain its highest value during radiotherapy. A consideration of the likely rate of clearance of gamma enolase from the cerebrospinal fluid and the time sequence of administration of the several chemotherapeutic agents in UKALL VIII suggests that asparaginase may be the main causative agent in the rise of this marker of neuronal damage.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6585185      PMCID: PMC1628534          DOI: 10.1136/adc.59.3.266

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  11 in total

Review 1.  Neurotoxicity of commonly used antineoplastic agents (first of two parts).

Authors:  H D Weiss; M D Walker; P H Wiernik
Journal:  N Engl J Med       Date:  1974-07-11       Impact factor: 91.245

2.  Psychiatric symptoms associated with L-asparaginase administration.

Authors:  J Holland; S Fasanello; T Onuma
Journal:  J Psychiatr Res       Date:  1974-05       Impact factor: 4.791

3.  Encephalopathy in acute leukaemia associated with methotrexate therapy.

Authors:  H E Kay; P J Knapton; J P O'Sullivan; D G Wells; R F Harris; E M Innes; J Stuart; F C Schwartz; E N Thompson
Journal:  Arch Dis Child       Date:  1972-06       Impact factor: 3.791

4.  Electroencephalogram changes secondary to asparaginase.

Authors:  J M Moure; J P Whitecar; G P Bodey
Journal:  Arch Neurol       Date:  1970-10

5.  Toxicity of L-asparginase in children with advanced leukemia.

Authors:  V J Land; W W Sutow; D J Fernbach; D M Lane; T E Williams
Journal:  Cancer       Date:  1972-08       Impact factor: 6.860

6.  The central nervous system in childhood leukemia. II. Subacute leukoencephalopathy.

Authors:  R A Price; P A Jamieson
Journal:  Cancer       Date:  1975-02       Impact factor: 6.860

Review 7.  L-Asparaginase: human toxicology and single agent activity in nonleukemic neoplasms.

Authors:  C M Haskell
Journal:  Cancer Treat Rep       Date:  1981

8.  The labelling of proteins to high specific radioactivities by conjugation to a 125I-containing acylating agent.

Authors:  A E Bolton; W M Hunter
Journal:  Biochem J       Date:  1973-07       Impact factor: 3.857

9.  Active transport of methotrexate from cerebrospinal fluid in humans.

Authors:  U Bode; I T Magrath; W A Bleyer; D G Poplack; D L Glaubiger
Journal:  Cancer Res       Date:  1980-07       Impact factor: 12.701

10.  Acute encephalopathy after initiation of cranial irradiation for meningeal leukaemia.

Authors:  A Oliff; W A Bleyer; D G Poplack
Journal:  Lancet       Date:  1978-07-01       Impact factor: 79.321

View more
  2 in total

Review 1.  Malignancy markers in the cerebrospinal fluid.

Authors:  M Koskiniemi
Journal:  Eur J Pediatr       Date:  1988-10       Impact factor: 3.183

2.  Evaluation of a radioimmunoassay for neuron specific enolase in small cell lung cancer.

Authors:  E H Cooper; T A Splinter; D A Brown; M F Muers; M D Peake; S L Pearson
Journal:  Br J Cancer       Date:  1985-09       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.